Frequency of hepatitis B virus mutant in asymptomatic hepatitis B virus carriers receiving prophylactic lamivudine during chemotherapy for hematologic malignancies.
暂无分享,去创建一个
G. Rossi | E. Cariani | E. Borlenghi | M. Motta | P. Turconi | A. Pelizzari
[1] E. Koay,et al. Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients , 2002, Alimentary pharmacology & therapeutics.
[2] D. Fong,et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation , 2002, Hepatology.
[3] O. Shibolet,et al. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. , 2002, Blood.
[4] Sheng-Nan Lu,et al. Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non‐Hodgkin's lymphoma , 2002, British journal of haematology.
[5] G. Rossi,et al. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy , 2001, British journal of haematology.
[6] F. Zoulim. Detection of hepatitis B virus resistance to antivirals. , 2001, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[7] K. Fischer,et al. Lamivudine resistance in hepatitis B: mechanisms and clinical implications. , 2001, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[8] W. Yeo,et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors , 2000, Journal of medical virology.
[9] T. Mok,et al. Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy , 1999, Journal of medical virology.
[10] G. Lau,et al. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] N. Leung,et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. , 1998, The New England journal of medicine.
[12] S. Shimano,et al. Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] T. Motokura,et al. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies: Survey in Japan, 1987‐1991 , 1996 .
[14] R. Dornsife,et al. In vitro potency of inhibition by antiviral drugs of hematopoietic progenitor colony formation correlates with exposure at hemotoxic levels in human immunodeficiency virus-positive humans , 1996, Antimicrobial agents and chemotherapy.
[15] A. Lok,et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. , 1991 .